Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

47.44USD
5 Mar 2015
Change (% chg)

$0.43 (+0.91%)
Prev Close
$47.01
Open
$46.96
Day's High
$47.50
Day's Low
$46.82
Volume
1,548,783
Avg. Vol
1,576,751
52-wk High
$47.88
52-wk Low
$36.66

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company’s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products,... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $71,374.48
Shares Outstanding(Mil.): 1,505.79
Dividend: 0.24
Yield (%): 2.03

Financials

  ABT.N Industry Sector
P/E (TTM): 41.96 38.99 40.21
EPS (TTM): 1.13 -- --
ROI: -- 17.01 16.34
ROE: -- 17.53 17.27
Search Stocks

Wall St. falls from records, led by technology stocks

NEW YORK - U.S. stocks finished down on Tuesday, a day after the S&P and Dow hit records, and the Nasdaq retreated with technology stocks.

03 Mar 2015

UPDATE 1-Mylan still on the prowl for deals, perhaps one by end 2015

March 2 - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.

02 Mar 2015

UPDATE 3-Bidvest makes $515 million bid for rest of Adcock Ingram

* Shares in Adcock jump more than four percent (Adds analyst comment)

23 Feb 2015

Abbott CEO losing no sleep over stronger dollar

- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics.

29 Jan 2015

Abbott CEO losing no sleep over stronger dollar

Jan 29 - Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics.

29 Jan 2015

BRIEF-Abbott says sees positive underlying momentum going into 2015

Jan 29 - Abbott Laboratories : * CEO says company sees "good positive underlying momentum in our businesses"

29 Jan 2015

Abbott Labs 2015 outlook largely in line with estimates

- Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results.

29 Jan 2015

UPDATE 1-Abbott Labs 2015 outlook largely in line with estimates

Jan 29 - Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results.

29 Jan 2015

EU approves Mylan purchase of Abbot generics, subject to conditions

BRUSSELS - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.

28 Jan 2015

EU approves Mylan purchase of Abbot generics, subject to conditions

BRUSSELS - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc , subject to conditions.

28 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $102.52 +0.87
Pfizer Inc. (PFE.N) $34.47 -0.17
Novartis AG (NOVN.VX) CHF96.30 +1.10
Merck & Co., Inc. (MRK.N) $57.98 +0.10
Sanofi SA (SASY.PA) €87.84 +0.39
AstraZeneca plc (AZN.L) 4,486.50p +63.00
GlaxoSmithKline plc (GSK.L) 1,571.00p +5.00
Eli Lilly and Co (LLY.N) $70.59 -0.06
Amgen, Inc. (AMGN.OQ) $159.60 +0.41
Boston Scientific Corporation (BSX.N) $16.97 +0.18

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$92.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks